Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine + hydromorphone vs hydromorphone for PONV after colorectal cancer surgery
ChiCTR2400090806Phase 4Not yet recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in colorectal cancer (CRC) (2 arms), sponsored by Peking University Shougang Hospital. Primary endpoint: Incidence of PONV within 48 hours after surgery. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400090806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090806.